These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31921377)

  • 1. Combining Prostate-Specific Antigen Parameters With Prostate Imaging Reporting and Data System Score Version 2.0 to Improve Its Diagnostic Accuracy.
    Baruah SK; Das N; Baruah SJ; Rajeev TP; Bagchi PK; Sharma D; Phukan M
    World J Oncol; 2019 Dec; 10(6):218-225. PubMed ID: 31921377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of the prostate health index vs. multiparametric magnetic resonance imaging for prostate cancer diagnosis in prostate biopsy.
    Stejskal J; Adamcová V; Záleský M; Novák V; Čapoun O; Fiala V; Dolejšová O; Sedláčková H; Veselý Š; Zachoval R
    World J Urol; 2021 Jun; 39(6):1889-1895. PubMed ID: 32761380
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Yang J; Li J; Xiao L; Zhou M; Fang Z; Cai Y; Tang Y; Hu S
    Cancer Imaging; 2023 Sep; 23(1):81. PubMed ID: 37667341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI.
    Liang L; Qi F; Cheng Y; Zhang L; Cao D; Cheng G; Hua L
    Sci Rep; 2021 Mar; 11(1):6048. PubMed ID: 33723287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml
    Wang C; Wang YY; Wang SY; Ding JX; Ding M; Ruan Y; Wang XH; Jing YF; Han BM; Xia SJ; Jiang CY; Zhao FJ
    Asian J Androl; 2021; 23(4):415-420. PubMed ID: 33473011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
    Wei X; Xu J; Zhong S; Zou J; Cheng Z; Ding Z; Zhou X
    Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified Predictive Model and Nomogram by Incorporating Prebiopsy Biparametric Magnetic Resonance Imaging With Clinical Indicators for Prostate Biopsy Decision Making.
    Pan JF; Su R; Cao JZ; Zhao ZY; Ren DW; Ye SZ; Huang RD; Tao ZL; Yu CL; Jiang JH; Ma Q
    Front Oncol; 2021; 11():740868. PubMed ID: 34589437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New model of PIRADS and adjusted prostatespecific antigen density of peripheral zone improves the detection rate of initial prostate biopsy: a diagnostic study.
    Huang C; Cai ZQ; Qiu F; Pu JX; Xi QL; Wei XD; Wang XM; Zhao XJ; Guo LC; Hou JQ; Huang YH
    Asian J Androl; 2023; 25(1):126-131. PubMed ID: 35488668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and prostate multiparametric magnetic resonance imaging findings as predictors of general and clinically significant prostate cancer risk: A retrospective single-center study.
    Massanova M; Vere R; Robertson S; Crocetto F; Barone B; Dutto L; Ahmad I; Underwood M; Salmond J; Patel A; Celentano G; Bhatt JR
    Curr Urol; 2023 Sep; 17(3):147-152. PubMed ID: 37448611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis.
    Wang S; Kozarek J; Russell R; Drescher M; Khan A; Kundra V; Barry KH; Naslund M; Siddiqui MM
    Eur Urol Oncol; 2024 Apr; 7(2):189-203. PubMed ID: 37640584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
    Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
    Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of the diagnostic accuracy across prostate health index, prostate health index density, and percentage free prostate-specific antigen for clinically significant prostate cancer: a prospective diagnostic study.
    Wu B; Shao Y; Lin X; Hasi C; Jia W; Wang D; Cao X
    Transl Androl Urol; 2023 Mar; 12(3):425-432. PubMed ID: 37032752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels.
    Tarcan T; Ozveri H; Biren T; Türkeri L; Akdas A
    Int J Urol; 1997 Jul; 4(4):362-7. PubMed ID: 9256325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When to biopsy Prostate Imaging and Data Reporting System version 2 (PI-RADSv2) assessment category 3 lesions? Use of clinical and imaging variables to predict cancer diagnosis at targeted biopsy.
    Lim CS; Abreu-Gomez J; Leblond MA; Carrion I; Vesprini D; Schieda N; Klotz L
    Can Urol Assoc J; 2021 Apr; 15(4):115-121. PubMed ID: 33007183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of prostate cancer using prostate imaging reporting and data system score and prostate-specific antigen density in biopsy-naive and prior biopsy-negative patients.
    Ryoo H; Kang MY; Sung HH; Chang Jeong B; Seo SI; Jeon SS; Lee HM; Jeon HG
    Prostate Int; 2020 Sep; 8(3):125-129. PubMed ID: 33102394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen density as the best predictor of low- to intermediate-risk prostate cancer: a cohort study.
    Park DH; Yu JH
    Transl Cancer Res; 2023 Mar; 12(3):502-514. PubMed ID: 37033352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone.
    Liu J; Dong B; Qu W; Wang J; Xu Y; Yu S; Zhang X
    Sci Rep; 2020 Mar; 10(1):5157. PubMed ID: 32198373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.